An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency
Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an
inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for
detoxification of ammonia. Individuals with OTC deficiency can build-up excess levels of
...
Age: 24 hours - 7 months
Gender: Male
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or
atezolizumab alone, as first-line treatment in participants with unresectable, locally
advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Age: 18 years - 66+
Gender: All
Bridge to HOPE: Hypothermic Oxygenated Perfusion Versus Cold Storage Prior to Liver Transplantation
This is a prospective, multi-center, controlled, randomized, pivotal study to evaluate the
safety and effectiveness of the VitaSmart Liver Machine Perfusion System by comparing
clinical outcomes in patients undergoing liver transplantation with ex-vivo liver
prese...
Age: 18 years - 66+
Gender: All
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and
Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Age: 18 years - 66+
Gender: All
TReatment for ImmUne Mediated PathopHysiology
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm,
randomized, controlled trial of immunosuppressive therapy for children with acute liver
failure. The study will determine if suppressing inflammatory responses with either
corticost...
Age: 1 year - 18 years
Gender: All
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver
fibrosis histological stage F2 or F3
Age: 18 years - 66+
Gender: All
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider
liver transplantation as an option, even if controversial. In sicker recipients, LT
results in immediate survival, but poor medium-term survival rates in some studies. The
scarcity...
Age: 18 - 80 years
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the
progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where
there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of
developing li...
Age: 18 years - 66+
Gender: All
Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver...
Age: 18 years - 66+
Gender: All
FAST (Focused Abbreviated Screening Technique)-MRI Study
The purpose of this study is to compare the diagnostic value of a reconstructed
abbreviated Magnetic Resonance Imaging (MRI) from a full clinical exam, compared to
ultrasound (US) for screening of liver cancer. Blood markers will be evaluated to
determine their corre...
Age: 18 years - 66+
Gender: All
